{"id":22174,"date":"2021-09-20T12:06:00","date_gmt":"2021-09-20T12:06:00","guid":{"rendered":"https:\/\/celonpharma.com\/?p=22174"},"modified":"2021-09-24T12:10:05","modified_gmt":"2021-09-24T12:10:05","slug":"current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/","title":{"rendered":"Current report 41\/2021 \u2013 Supplement to Current Report No 35\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A."},"content":{"rendered":"\n

Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodical information<\/p>\n\n\n\n

Content of the report:<\/p>\n\n\n\n

The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby publishes a supplement to current report No. 35\/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company’s ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:<\/p>\n\n\n\n

12) determination of the amount of the total costs which have been included in the issue costs:<\/p>\n\n\n\n

As of the date of this report, the total costs incurred by the Company in connection with the issue of D-series shares amounted to PLN 13,358,254.97, including the costs of:<\/p>\n\n\n\n

a) preparing and implementing the offer \u2013 PLN 10,499,385.06;<\/p>\n\n\n\n

b) the underwriters’ remuneration, separately for each underwriter \u2013 not applicable;<\/p>\n\n\n\n

c) preparing of the prospectus, including costs of advisory services \u2013 PLN 2,075,140.04;<\/p>\n\n\n\n

d) promoting the offer \u2013 PLN 783,729.87.<\/p>\n\n\n\n

The settlement of the costs of the issue of D-series shares in the accounting books will be made by way of reducing the Company’s supplementary capital.<\/p>\n\n\n\n

13) The average cost of conducting the subscription per unit of security subscribed:<\/p>\n\n\n\n

The average cost incurred by the Company per D-series share amounted to approximately PLN 2.23.<\/p>\n","protected":false},"excerpt":{"rendered":"

The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby publishes a supplement to current report No. 35\/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company’s ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[46],"tags":[],"class_list":["post-22174","post","type-post","status-publish","format-standard","hentry","category-current-reports"],"acf":[],"yoast_head":"\nCurrent report 41\/2021 \u2013 Supplement to Current Report No 35\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A. - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current report 41\/2021 \u2013 Supplement to Current Report No 35\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A. - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby publishes a supplement to current report No. 35\/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company's ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-20T12:06:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-24T12:10:05+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"Current report 41\\\/2021 \u2013 Supplement to Current Report No 35\\\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A.\",\"datePublished\":\"2021-09-20T12:06:00+00:00\",\"dateModified\":\"2021-09-24T12:10:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\\\/\"},\"wordCount\":219,\"articleSection\":[\"Current reports\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\\\/\",\"name\":\"Current report 41\\\/2021 \u2013 Supplement to Current Report No 35\\\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A. - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2021-09-20T12:06:00+00:00\",\"dateModified\":\"2021-09-24T12:10:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current report 41\\\/2021 \u2013 Supplement to Current Report No 35\\\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current report 41\/2021 \u2013 Supplement to Current Report No 35\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A. - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/","og_locale":"en_US","og_type":"article","og_title":"Current report 41\/2021 \u2013 Supplement to Current Report No 35\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A. - Celon Pharma","og_description":"The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby publishes a supplement to current report No. 35\/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company's ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:","og_url":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/","og_site_name":"Celon Pharma","article_published_time":"2021-09-20T12:06:00+00:00","article_modified_time":"2021-09-24T12:10:05+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"Current report 41\/2021 \u2013 Supplement to Current Report No 35\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A.","datePublished":"2021-09-20T12:06:00+00:00","dateModified":"2021-09-24T12:10:05+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/"},"wordCount":219,"articleSection":["Current reports"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/","url":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/","name":"Current report 41\/2021 \u2013 Supplement to Current Report No 35\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A. - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2021-09-20T12:06:00+00:00","dateModified":"2021-09-24T12:10:05+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/current-report-41-2021-supplement-to-current-report-no-35-2021-on-the-summary-of-subscription-of-ordinary-d-series-bearer-shares-of-celon-pharma-s-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Current report 41\/2021 \u2013 Supplement to Current Report No 35\/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A."}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=22174"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22174\/revisions"}],"predecessor-version":[{"id":22176,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22174\/revisions\/22176"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=22174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=22174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=22174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}